Navigation Links
Favrille to Present at BIO InvestorForum
Date:10/2/2007

Live Webcast from the Palace Hotel in San Francisco on Wednesday, October

10th

SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that Tamara Seymour, Chief Financial Officer, will present at the Biotechnology Industry Organization (BIO) InvestorForum at 10:15 a.m. Pacific time on Wednesday, October 10, 2007. The conference will be held at the Palace Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Ms. Seymour will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until November 10, 2007.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...IENNA, Austria, November 6 EUCODIS...nufacturing, and marketing enzymes for the,chemica...o a research,agreement with Bio Sidus, the leading..., The agreement gives EUCODIS Bioscience exclu...t - to Bio Sidus, proprietary collection of,psychr...
(Date:11/6/2009)...RD, Calif., Nov. 6 Intarcia Therap...its ITCA 650 (DUROS® continuous delivery of e...etes at the Ninth Annual Diabetes Technology Meeti...newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,...e Via ITCA 650 Lowers Plasma Glucose, HbA1c and Re...
(Date:11/5/2009)...NGTON, Colo., Nov. 5 The endangere...n the western U.S. This rare carnivore feeds on p...le to plague and often entire population die-offs ...ice (FWS) has implemented a ferret breeding progra...into their formerly native habitat. Unfortunately...
(Date:11/5/2009)...rence Call on Thursday, November 5, 2009 at 4:30 p...Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmace...AQ: OGXI ) today reported unaudited financial res...eptember 30, 2009 and reviewed the Company,s highl...lowing consolidated results reflect the operations...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
..., , AquaPure Genomic DNA Isolation... yield range: 250 g DNA (15-ml tube prep), ,... 1. Add 1 ml body fluid (e.g., cerebrospinal fl...ovial fluid, urine, whole blood, milk) to a steril... cell lysis solution. Pipet up and down several ti...
..., Andrew Conn, Lindy Durrant, and Ian Spendl...tingham City Hospital, Hucknall Road,Nottingham... , Gene gun immunization through the skin...of DNA vaccine delivery, and has been shown to be ... in animal models to both infectious diseases and ...
..., Jolanta Kolodziejek, MSc, and Professor No...roup, Institute of Virology, University of Veterin...1, A 1210 Vienna, Austria , , ...emplate employed in sequencing PCR (cycle sequenci...eotide sequencing. The presence of , cont...
Other Biology Technology:Genomic DNA Isolation From 1 ml of Body Fluid 2Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 2Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 3Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 4Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 5Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 6Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 7Delivery of pCMV-S DNA Using the Helios Gene Gun System Is Superior to Intramuscular Injection in Balb/c Mice 8Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 2Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 3Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 4
(Date:11/6/2009)...open for the Society of Interventional Radiology,s...ies" Webinar, which will provide the latest update...iver tumors, kidney tumor ablation and lung tumor ...ians, scientists and allied health professionals d...ring advances in image-guided therapy. , The Web...
(Date:11/6/2009)... -- Auburn Hills, MI-based Law Enforcement Intelli...cker system and patent-pending Biometric Access Co...Health and Human Services, National Institutes of ...stem will support the NIH,s entire police force th...cal research agency. The project is expected to b...
(Date:11/5/2009)...ale University have developed synthetic molecules ... HIV and HIV-infected cells, as well as to prostat...n the Journal of the American Chemical Society , ...se diseases. , The molecules called "antibody-...tibody-recruiting molecule targeting prostate canc...
Breaking Biology News(10 mins):Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 1Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 2Discovery of natural odors could help develop mosquito repellents 13710 1Discovery of natural odors could help develop mosquito repellents 13710 2Discovery of natural odors could help develop mosquito repellents 13710 3Senator Ted Kennedy 3A A Member of the NAMI Family 55466 1Senator Ted Kennedy 3A A Member of the NAMI Family 55466 2
...ly reside on the skin of healthy people can cause ... researchers at the Swedish medical university Kar...or why a certain kind of staphylococcus can attach...osystems: the bacteria are like tufted, self-adhes...elf on the child,s skin and mucous membranes direc...
... limestone countertop, a practiced eye and Google ... of fossils that may shed light on the origins of ...ous story, featuring University of Michigan paleon... Sanders, is the subject of a segment on the award...ently airing on public television stations (Episod...
...y Sanders today joined UC San Diego Chancellor Mar... to announce their support for a regional partners...gae into biofuels. , Speaking at a news conferenc...hers said the San Diego region, now home to more t...jor center for renewable energy development, as sc...
Other Biology News:Tufted bacteria cause infection in premature babies 2Google Earth aids discovery of early African mammal fossils 2Google Earth aids discovery of early African mammal fossils 3Regional partnership to develop algal biofuels gets backing of San Diego leaders 2Regional partnership to develop algal biofuels gets backing of San Diego leaders 3Regional partnership to develop algal biofuels gets backing of San Diego leaders 4Regional partnership to develop algal biofuels gets backing of San Diego leaders 5Regional partnership to develop algal biofuels gets backing of San Diego leaders 6
Mouse Anti-Human huntingtin Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
PureLink HiPure Plasmid Filter Midiprep Kit from Invitrogen
ViraPower UbC Lentiviral Gateway Expression Kit from Invitrogen
ViraPower Lentiviral Packaging Mix from Invitrogen
Biology Products: